J&J Fights Attys' Pursuit Of Confidential Risperdal Docs
Law360, Philadelphia (December 18, 2013, 6:05 PM EST) -- A Johnson & Johnson unit argued in Pennsylvania court Monday that the public release of discovery documents in a slew of state product liability cases, pending as part of a mass tort program, over the antipsychotic drug Risperdal would prejudice the drugmaker.
Janssen Pharmaceuticals Inc. argued that the plaintiffs' counsel were requesting the release of the documents as part of a coordinated smear campaign, according to a brief.
The plaintiffs — whose complaint claims Risperdal caused gynecomastia, or abnormal growth of breast tissue in adolescent boys — have argued that the protected material consisted of observations about the effectiveness and risks...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!